PDF(Pubmed)
Abstract：
The COVID-19 pandemic has resulted in many therapies, of which many are repurposed and used for other diseases in the last decade such in Influenza and Ebola. We intend to provide a robust foundation for cardiovascular outcomes of the therapies to better understand the rationale for the clinical trials that were conducted during the COVID-19 pandemic, and to gain more clarity on the steps moving forward should the repurposing provide clinical benefit in pandemic situations. With this state-of-the-art review, we aim to improve the understanding of the cardiovascular involvement of the therapies prior to, during, and after the COVID-19 pandemic to provide meaningful findings to the cardiovascular specialists and clinical trials for therapies, moving on from the period of pandemic urgency.
摘要：
COVID-19大流行导致了许多治疗方法，在过去的十年中，其中许多被重新利用并用于其他疾病，例如流感和埃博拉。我们打算为治疗的心血管结局提供坚实的基础，以更好地了解在COVID-19大流行期间进行的临床试验的基本原理，并更清楚地了解如果重新利用在大流行情况下提供临床益处，前进的步骤。有了这份最新的审查，我们的目标是在治疗之前提高对心血管疾病的理解，during,在COVID-19大流行之后，为心血管专家和临床试验提供有意义的发现，从流行病的紧急时期开始。
